Provided by Tiger Trade Technology Pte. Ltd.

Travere Therapeutics, Inc.

52.35
+0.31000.60%
Volume:501.64K
Turnover:26.25M
Market Cap:4.93B
PE:-109.88
High:52.71
Open:52.07
Low:51.63
Close:52.04
52wk High:68.73
52wk Low:22.59
Shares:94.26M
Float Shares:92.77M
Volume Ratio:0.25
T/O Rate:0.54%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.4764
EPS(LYR):-0.2864
ROE:-236.35%
ROA:-3.73%
PB:201.23
PE(LYR):-182.82

Loading ...

Travere Therapeutics director Roy D. Baynes disposes of USD 431,145 common shares

Reuters
·
May 05

Travere Therapeutics Q1 product sales rise on FILSPARI demand

Reuters
·
May 05

Travere Q1 FY26 net loss narrows to $37.1 million; net product sales climb 64.1% to $124.5 million

Reuters
·
May 05

BRIEF-Travere Therapeutics Q1 EPS USD -0.4

Reuters
·
May 05

Travere Therapeutics Q1 Operating Income USD -36.915 Million

THOMSON REUTERS
·
May 05

Press Release: Travere Therapeutics Reports First Quarter 2026 Financial Results

Dow Jones
·
May 05

Travere Therapeutics Inc expected to post a loss of 26 cents a share - Earnings Preview

Reuters
·
May 02

Travere Therapeutics (TVTX) Gets a Buy from Guggenheim

TIPRANKS
·
Apr 29

Press Release: Travere Therapeutics to Report First Quarter 2026 Financial Results

Dow Jones
·
Apr 28

Travere Therapeutics to report quarterly results, host conference call

Reuters
·
Apr 28

A Look At Travere Therapeutics (TVTX) Valuation After FILSPARI’s Expanded FDA Approval In FSGS

Simply Wall St.
·
Apr 25

Travere Therapeutics Inc : Jefferies Raises Target Price to $50 From $42

THOMSON REUTERS
·
Apr 24

Travere Therapeutics (TVTX) Receives a Buy from Piper Sandler

TIPRANKS
·
Apr 24

A Look At Travere Therapeutics (TVTX) Valuation After FDA Expands FILSPARI Approval For FSGS

Simply Wall St.
·
Apr 18

Travere Therapeutics (TVTX) Gets a Buy from Evercore ISI

TIPRANKS
·
Apr 17

Travere director Gary Lyons disposes of common shares worth $328,560

Reuters
·
Apr 17

Travere director Roy D. Baynes disposes of 32,750 shares worth $1,345,155

Reuters
·
Apr 17

Travere Therapeutics CAO Sandra Calvin disposes of common shares worth $902,565.39

Reuters
·
Apr 17

BRIEF-FDA Approves Treatment For Patients With Focal Segmental Glomerulosclerosis

Reuters
·
Apr 17

FDA: Approved Treatment for Patients With Focal Segmental Glomerulosclerosis

THOMSON REUTERS
·
Apr 17